Found: 62
Select item for more details and to access through your institution.
Pleuric presentation of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue: a case report and a review of the literature.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 21, p. 5459, doi. 10.3390/ijms20215459
- By:
- Publication type:
- Article
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 14, p. 3548, doi. 10.3390/ijms20143548
- By:
- Publication type:
- Article
A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 9, p. 2876, doi. 10.3390/jcm9092876
- By:
- Publication type:
- Article
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.
- Published in:
- Journal of Clinical Medicine, 2019, v. 8, n. 10, p. 1695, doi. 10.3390/jcm8101695
- By:
- Publication type:
- Article
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network.
- Published in:
- Journal of Clinical Medicine, 2019, v. 8, n. 6, p. 877, doi. 10.3390/jcm8060877
- By:
- Publication type:
- Article
IgG-k/IgG-λ Para-Osseous Plasmacytoma Relapsed as Soft-Tissue Plasmacytoma with IgA-k Immunophenotype: A Case Report and Review of the Literature on Related Biochemical Aspects.
- Published in:
- Hematology Reports, 2024, v. 16, n. 3, p. 541, doi. 10.3390/hematolrep16030052
- By:
- Publication type:
- Article
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study
- Published in:
- Stem Cell Research & Therapy, 2015, v. 6, n. 1, p. 1, doi. 10.1186/s13287-015-0033-1
- By:
- Publication type:
- Article
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multiple Myeloma Working Party study
- Published in:
- Stem Cell Research & Therapy, 2015, v. 6, n. 1, p. 64, doi. 10.1186/s13287-015-0033-1
- By:
- Publication type:
- Article
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).
- Published in:
- Annals of Hematology, 2019, v. 98, n. 2, p. 361, doi. 10.1007/s00277-018-3524-1
- By:
- Publication type:
- Article
Proteasome Inhibitors Synergize with Tumor Necrosis Factor-Related Apoptosis-Induced Ligand to Induce Anaplastic Thyroid Carcinoma Cell Death.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2007, v. 92, n. 5, p. 1938, doi. 10.1210/jc.2006-2157
- By:
- Publication type:
- Article
Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma.
- Published in:
- Panminerva Medica, 2021, v. 63, n. 1, p. 13, doi. 10.23736/S0031-0808.20.04141-5
- By:
- Publication type:
- Article
Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study.
- Published in:
- Cancers, 2023, v. 15, n. 16, p. 4036, doi. 10.3390/cancers15164036
- By:
- Publication type:
- Article
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection.
- Published in:
- Cancers, 2022, v. 14, n. 5, p. 1173, doi. 10.3390/cancers14051173
- By:
- Publication type:
- Article
Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study.
- Published in:
- Cancers, 2021, v. 13, n. 23, p. 6017, doi. 10.3390/cancers13236017
- By:
- Publication type:
- Article
Inhibition of TLR4 Signaling Affects Mitochondrial Fitness and Overcomes Bortezomib Resistance in Myeloma Plasma Cells.
- Published in:
- Cancers, 2020, v. 12, n. 8, p. 1999, doi. 10.3390/cancers12081999
- By:
- Publication type:
- Article
Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significance.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 6, p. 922, doi. 10.1111/ejh.14105
- By:
- Publication type:
- Article
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
- Published in:
- European Journal of Haematology, 2022, v. 108, n. 3, p. 178, doi. 10.1111/ejh.13723
- By:
- Publication type:
- Article
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.643490
- By:
- Publication type:
- Article
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2021.624405
- By:
- Publication type:
- Article
Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
- Published in:
- European Journal of Haematology, 2014, v. 93, n. 3, p. 207, doi. 10.1111/ejh.12325
- By:
- Publication type:
- Article
Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.
- Published in:
- European Journal of Haematology, 2011, v. 86, n. 3, p. 216, doi. 10.1111/j.1600-0609.2010.01570.x
- By:
- Publication type:
- Article
Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
- Published in:
- Chemotherapy (0009-3157), 2019, v. 64, n. 2, p. 110, doi. 10.1159/000502473
- By:
- Publication type:
- Article
Serum free light chains and multiple myeloma: Is it time to extend their application?
- Published in:
- Clinical Case Reports, 2020, v. 8, n. 4, p. 617, doi. 10.1002/ccr3.2636
- By:
- Publication type:
- Article
A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?
- Published in:
- Clinical Case Reports, 2019, v. 7, n. 9, p. 1629, doi. 10.1002/ccr3.2292
- By:
- Publication type:
- Article
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells.
- Published in:
- Frontiers in Pharmacology, 2015, p. 1, doi. 10.3389/fphar.2015.00226
- By:
- Publication type:
- Article
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 5, p. e456, doi. 10.1016/j.clml.2020.12.022
- By:
- Publication type:
- Article
Maintenance Therapy vs Re-treatment at Biochemical Relapse vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II, Randomized Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e271, doi. 10.1016/j.clml.2019.09.447
- By:
- Publication type:
- Article
Ixazomib inhibits osteoclastogenesis and promotes osteogenic differentiation in vitro.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e195, doi. 10.1016/j.clml.2019.09.325
- By:
- Publication type:
- Article
TLR4 signaling drives mesenchymal stromal cells (MSC) commitment to promote tumor microenvironment transformation in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e90, doi. 10.1016/j.clml.2019.09.147
- By:
- Publication type:
- Article
Tryptophan Shortage Due to IDO-1 Expressed by High-Density Neutrophils Induce Immune-Suppression and Plasma Cell Fitness in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S246, doi. 10.1016/j.clml.2018.07.143
- By:
- Publication type:
- Article
High-Density Neutrophils are Immunosuppressive in Multiple Myeloma Due to Increased Arginase-1, Predictor of Short Progression Free Survival.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S69, doi. 10.1016/j.clml.2016.07.101
- By:
- Publication type:
- Article
Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies.
- Published in:
- International Journal of Cancer, 2012, v. 131, n. 9, p. 2197, doi. 10.1002/ijc.27482
- By:
- Publication type:
- Article
Correction: TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma.
- Published in:
- 2019
- By:
- Publication type:
- Correction Notice
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma.
- Published in:
- Cell Death & Disease, 2019, v. 10, n. 10, p. N.PAG, doi. 10.1038/s41419-019-1959-5
- By:
- Publication type:
- Article
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3290
- By:
- Publication type:
- Article
A real‐life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3289
- By:
- Publication type:
- Article
Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 987, doi. 10.1002/hon.3041
- By:
- Publication type:
- Article
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 1009, doi. 10.1002/hon.3035
- By:
- Publication type:
- Article
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 4, p. 704, doi. 10.1002/hon.3031
- By:
- Publication type:
- Article
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up.
- Published in:
- Hematological Oncology, 2012, v. 30, n. 4, p. 180, doi. 10.1002/hon.1022
- By:
- Publication type:
- Article
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors.
- Published in:
- Hematological Oncology, 2012, v. 30, n. 1, p. 27, doi. 10.1002/hon.988
- By:
- Publication type:
- Article
Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils.
- Published in:
- Biomedicines, 2021, v. 9, n. 10, p. 1455, doi. 10.3390/biomedicines9101455
- By:
- Publication type:
- Article
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Resistance of papillary thyroid cancer stem cells to chemotherapy.
- Published in:
- Oncology Letters, 2016, v. 12, n. 1, p. 687, doi. 10.3892/ol.2016.4666
- By:
- Publication type:
- Article
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1157610
- By:
- Publication type:
- Article
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.890376
- By:
- Publication type:
- Article
Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over.
- Published in:
- Acta Haematologica, 2024, v. 147, n. 4, p. 493, doi. 10.1159/000521112
- By:
- Publication type:
- Article